Spurred by a recent warning from the Food and Drug Administration, some plaintiffs firms, including Milberg Weiss, have identified gadolinium suits as a burgeoning area of litigation. Used to treat diseased kidneys, the chemical has plaintiffs lawyers salivating at the thought of a new arena of billion-dollar mass torts. But one firm wants to take it one suit at a time. Jeffrey Kaiser, a partner at Levin Simes Kaiser & Gornick, says the work on the first case will “set the tone” for the other cases.
Sorry, the comment form is closed at this time.